PhoreMost, a Cambridge, UK-based biopharmaceutical company, raised £4m in Series A equity and grant funding.
The round was led by Amadeus Capital Partners and Abcam founder Jonathan Milner with participation from Cambridge Enterprise and angels. In conjunction with the funding, Hermann Hauser at Amadeus, joined PhoreMost’s Board of Directors.
The company intends to use the funds to develop a pipeline of selective and patient-specific drugs for cancer and other conditions currently lacking therapeutic options as well as new ways in which to apply such treatments cost-effectively.
Founded by Dr Chris Torrance, CEO, and Ashok Venkitaraman, Ursula Zoellner Professor of Cancer Research at the University of Cambridge and Director of the Medical Research Council (MRC) Cancer Unit, PhoreMost has developed a screening platform called “SiteSeeker”, which can identify cryptic druggable sites on these targets, and ways in which they can be rapidly drugged with novel small-molecule therapies.
FinSMEs
07/04/2015